EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Dentsply Sirona Inc (XRAY) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Dentsply Sirona Inc $5.89, price $9.78, upside -39.8%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US24906P1093

DS Dentsply Sirona Inc logo Some data Sep 24, 2026

Dentsply Sirona Inc

XRAY · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $5.89 · Strongly overvalued (−40%)
!Quality 53/100
!Weak Growth (revenue 5y +2.0 %/yr)
!Loss-making · -17.1% net margin (TTM)
!High debt · generates free cash flow
·4.91% dividend yield
!Trails peers (5/14)
!Narrow moat 23/100
✓Insider activity 78/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range $1.22 to $12.42
!Weak on future: 1 out of 100
Watch Dentsply Sirona Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$59.95 $9.38 Fair Value $5.89 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $9.38 – $59.95 · fair‑value band $1.22 – $12.42 · the $9.78 price screens above the $5.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Dentsply Sirona in your weekly email

Every Wednesday you see whether Dentsply Sirona is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.

Show more

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Stock analysis

Dentsply Sirona Inc (XRAY) currently trades at $9.78, while our model-based Fair Value estimate is $5.89, implying the stock looks roughly 66.1% overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of $9.47 per share, and 1 of the 8 models we run sit above the $9.78 price.

Bear case: the Growth DCF group reads lowest at $1.04, and 7 of the 8 models stay below the price. Evidence for this calculation is medium.

Scenario range: $1.22 (bear) to $12.42 (bull), the price of $9.78 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Dentsply Sirona Inc reported revenue of $3.7B in FY2025 versus $4.2B in FY2021, a compound −3.4%/yr. Reported net income was −$598M in FY2025.

Key figures

Market cap $2.1B · P/S ratio 0.57 · EPS (TTM) $−3.15 · Dividend yield 4.9% · Net margin −16.3% · Return on equity −37.7% · Return on assets (EBIT) −3.5% · Operating margin 3.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 33% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −40%, XRAY screens richer than that median.

Fair Value models

Bear $1.22 Fair Value $5.89 Bull $12.42
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $1.12 $6.52 $14.61 72
Growth DCF $1.22 $5.89 $12.42 71
5Y Revenue Exit n/a $0.9600 $4.81 69
All 9 models by family
DCF Models
FCF DCF $1.12 $6.52 $14.61 72
5Y Revenue Exit n/a $0.9600 $4.81 69
10Y Revenue Exit n/a $1.94 $6.00 64
Dividend Discount
Gordon GGM $5.61 $11.18 $16.93 67
DDM Multi-Stage $5.61 $9.47 $11.80 67
Multiples
EV/Revenue n/a n/a $0.3400 50
Asset-Based
NCAV (Graham) $3.34 $4.48 $6.69 54
Growth DCF
Growth DCF $1.22 $5.89 $12.42 71
Rev-Margin DCF n/a $1.04 $4.79 69

Open the full fair value analysis →

Notify me when XRAY reaches fair value

Put XRAY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 45 · Market factors (momentum, volatility) 28

Profitability 22
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 16
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 99
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic). Over 10 years: +3.2% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.8% (2019) → −23.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +18.2% a year for the price and −1.2% for the forecasts.
Forecast 2026 (sales)−2.6%
Forecast 2027 (sales)+2.1%
Projected 2028 (sales)+2.1%
Projected 2029 (sales)+2.1%
Projected 2030 (sales)+2.1%

XRAY screens 66% overvalued. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Dentsply Sirona Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −40% · Below median
Profitability
Return on assets 2% · Below median
Net margin (TTM) −17% · Bottom 25%
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth 0% · Below median
Dividend yield (TTM) 4.9% · Top 25%
Balance sheet
Debt / equity 1.50× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.57× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.57× · Cheapest 25%
P/FCF 20.3× · Pricier than median
EV/EBITDA 6.8× · Cheapest 25%
PEG 0.75× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)1 · sector 31
PAST (return on equity)0 · sector 25
HEALTH (low debt)25 · sector 96
DIVIDEND (yield)98 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dentsply Sirona Inc · Fair Value
$5.89 −66%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Dentsply Sirona Inc Fair Value". https://www.fairvalue-calculator.com/stock/XRAY

Frequently asked questions

Is Dentsply Sirona Inc (XRAY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $5.89 versus a price of $9.78, about −40% upside (overvalued).
What is the fair value of XRAY?
Our model-based fair value for Dentsply Sirona Inc is $5.89 (as of Sep 24, 2026), built from audited fundamentals. The current price: $9.78.
What is the quality score of XRAY?
Dentsply Sirona Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dentsply Sirona Inc (XRAY)?
Our model-based price target is the fair value of $5.89 (as of Sep 24, 2026) from 9 valuation models. Cautious scenario $1.22, optimistic scenario $12.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Dentsply Sirona Inc stock forecast for 2026?
Our models put fair value at $5.89, about −40% upside versus a price of $9.78 (overvalued). Cautious scenario $1.22, optimistic scenario $12.42. The calculation is refreshed regularly with new filings.
What is the revenue of Dentsply Sirona Inc (XRAY)?
Dentsply Sirona Inc reported trailing-twelve-month revenue of about $3.7B (latest available figure, as of Sep 24, 2026).
Does Dentsply Sirona Inc pay a dividend?
Dentsply Sirona Inc currently shows a dividend yield of about 4.91% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Dentsply Sirona Inc (XRAY)?
For today's price to be fair in a discounted-cash-flow model, Dentsply Sirona Inc would have to grow free cash flow by +21.0 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of XRAY use?
Our models discount Dentsply Sirona Inc at 9.5 %: a base by market capitalisation (mid), damped by beta 0.91, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dentsply Sirona Inc that is +21.0 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has Dentsply Sirona Inc (XRAY) delivered so far?
Over the past 5 years revenue at Dentsply Sirona Inc grew +2.0 % a year. The price currently implies +21.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dentsply Sirona Inc (XRAY) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Dentsply Sirona Inc (+21.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dentsply Sirona Inc (XRAY)?
The free-cash-flow yield on the price is 5.33 %: that much free cash flow Dentsply Sirona Inc produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dentsply Sirona Inc (XRAY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dentsply Sirona Inc it is $5.89 per share (as of Sep 24, 2026), against a price of $9.78. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Dentsply Sirona Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, XRAY trades above its calculated fair value: price $9.78, fair value $5.89, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XRAY?
No. The price is what the market pays today ($9.78); the fair value is what the company's own numbers justify ($5.89). For Dentsply Sirona Inc the two are $3.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dentsply Sirona Inc worth?
The market values Dentsply Sirona Inc at about $2.1B (market capitalisation, as of Sep 24, 2026). Per share that is $9.78; our models calculate a fair value of $5.89 per share.
What do the bullish and bearish scenarios say about XRAY?
Our models span a range for Dentsply Sirona Inc: cautious scenario $1.22, base $5.89, optimistic $12.42 per share (as of Sep 24, 2026, price $9.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of XRAY?
The PEG ratio of Dentsply Sirona Inc is 0.75 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Dentsply Sirona Inc (XRAY)?
Balance-sheet figures for Dentsply Sirona Inc (as of Sep 24, 2026): return on equity −37.7%, debt of 1.50 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is XRAY from its 52-week high?
Dentsply Sirona Inc trades at $9.78, about 33% below its 52-week high of $14.68 and 4% above the low of $9.38 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.89 is for.
Which stocks are comparable to Dentsply Sirona Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dentsply Sirona Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $9.78, calculated fair value $5.89 (−40%), Quality Score 53/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XRAY calculated?
We run Dentsply Sirona Inc through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Dentsply Sirona Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dentsply Sirona Inc (XRAY)?
The closing price on Sep 23, 2026 was $9.78. Our model-based fair value is $5.89, about −40% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dentsply Sirona Inc right now?
The model range is unusually wide ($1.22 to $12.42). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Dentsply Sirona Inc

How large is the market capitalisation of Dentsply Sirona Inc (XRAY)?
The market capitalisation of Dentsply Sirona Inc is $2.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dentsply Sirona Inc (XRAY)?
The price-to-sales ratio of Dentsply Sirona Inc is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dentsply Sirona Inc (XRAY)?
Earnings per share at Dentsply Sirona Inc are $−3.15. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dentsply Sirona Inc (XRAY)?
The dividend yield of Dentsply Sirona Inc is 4.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dentsply Sirona Inc (XRAY)?
The net margin of Dentsply Sirona Inc is −16.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dentsply Sirona Inc (XRAY)?
The return on equity (ROE) of Dentsply Sirona Inc is −37.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dentsply Sirona Inc (XRAY)?
On an EBIT basis the return on assets of Dentsply Sirona Inc is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dentsply Sirona Inc (XRAY)?
The operating margin of Dentsply Sirona Inc is 3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dentsply Sirona Inc (XRAY)?
Revenue at Dentsply Sirona Inc is growing +0.1% versus a year earlier (3y avg −2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dentsply Sirona Inc (XRAY)?
Earnings per share at Dentsply Sirona Inc are growing +15.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Dentsply Sirona Inc (XRAY) carry?
The net debt of Dentsply Sirona Inc is $2.1B (fiscal year 2025, ≈ 20.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dentsply Sirona Inc in the live analysis

One click puts Dentsply Sirona Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.